Clinical Trial Update: Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel plus everolimus (RAD001) in bladder cancer/urothelial carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Bladder Cancer | Phase 2 | Status: TERMINATED